Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Director | March 14, 2017 | March 16, 2017 |
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Director · Chief Executive Officer | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date March 14, 2017 · Filed March 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2027-03-14 | Direct | 75,000 |
Reported balance
After 2017-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-14 · Grant · Acquired 75,000 · Balance 75,000 F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.
RELMADA THERAPEUTICS, INC.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,500,000 |
Ending reported balance
After 2026-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-09 · Purchase · Acquired 100,000 · Balance 1,400,000 F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2: Purchase prices range from $4.15 to $4.22 per share, inclusive. Row 2 · 2026-09-10 · Purchase · Acquired 100,000 · Balance 1,500,000 F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F3: Purchase prices range from $4.03 to $4.11 per share, inclusive |
Filing footnotes · ownership attribution and instrument terms
F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2: Purchase prices range from $4.15 to $4.22 per share, inclusive.
F3: Purchase prices range from $4.03 to $4.11 per share, inclusive
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2021 Filed Mar 11, 2021 22:51 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 2,983 | $35.09 | $104,675.86 |
DisclosureSEC source: 0001213900-21-014918 · ownership.xml · nonDerivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,774 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F5 · price: Sales prices range from $35.00 to $35.37 per share, inclusive. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:51 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 10,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-014918 · ownership.xml · derivative · entry 5 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,211 Underlying: Common Stock · 10,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:51 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,800 | $36.32 | $65,380.32 |
DisclosureSEC source: 0001213900-21-014918 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,757 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $36.02 to $36.65 per share, inclusive. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:51 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 5,217 | $35.42 | $184,788.75 |
DisclosureSEC source: 0001213900-21-014918 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,937 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.00 to $35.94 per share, inclusive. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:51 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 10,000 | $3.24 | $32,400.00 |
DisclosureSEC source: 0001213900-21-014918 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:50 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 10,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-012174 · ownership.xml · derivative · entry 5 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,211 Underlying: Common Stock · 10,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:50 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 303 | $35.55 | $10,770.65 |
DisclosureSEC source: 0001213900-21-012174 · ownership.xml · nonDerivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,774 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F5 · price: Sales prices range from $35.45 to $35.65 per share, inclusive. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:50 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 4,860 | $34.70 | $168,658.52 |
DisclosureSEC source: 0001213900-21-012174 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,077 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $34.41 to $35.33 per share, inclusive. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:50 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 4,837 | $33.69 | $162,962.88 |
DisclosureSEC source: 0001213900-21-012174 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,937 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $33.34 to $34.28 per share, inclusive. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 21:50 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 10,000 | $3.24 | $32,400.00 |
DisclosureSEC source: 0001213900-21-012174 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 1,446 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-009699 · ownership.xml · derivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,211 Underlying: Common Stock · 1,446 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,446 | $35.43 | $51,238.43 |
DisclosureSEC source: 0001213900-21-009699 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,774 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.14 to $35.96 per share, inclusive. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:10 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 1,446 | $3.24 | $4,685.04 |
DisclosureSEC source: 0001213900-21-009699 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 00:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,930 | $35.28 | $68,097.16 |
DisclosureSEC source: 0001213900-21-008204 · ownership.xml · nonDerivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,774 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F5 · price: Sales prices range from $35.00 to $35.64 per share, inclusive Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 00:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 5,963 | $35.21 | $209,938.74 |
DisclosureSEC source: 0001213900-21-008204 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,704 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $35.00 to $35.80 per share, inclusive Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 11,206 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-008204 · ownership.xml · derivative · entry 5 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,657 Underlying: Common Stock · 11,206 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,313 | $35.03 | $116,048.76 |
DisclosureSEC source: 0001213900-21-008204 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,667 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.00 to $35.29 per share, inclusive. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:25 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 11,206 | $3.24 | $36,307.44 |
DisclosureSEC source: 0001213900-21-008204 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 22:40 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 100 | $35.00 | $3,500.00 |
DisclosureSEC source: 0001213900-21-006834 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,874 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:42 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 13,281 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-006837 · ownership.xml · derivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,863 Underlying: Common Stock · 13,281 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:42 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 13,281 | $3.24 | $43,030.44 |
DisclosureSEC source: 0001213900-21-006837 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:40 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 3,278 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-006834 · ownership.xml · derivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,144 Underlying: Common Stock · 3,278 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:40 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 3,178 | $35.08 | $111,469.62 |
DisclosureSEC source: 0001213900-21-006834 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,874 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.00 to $35.30 per share, inclusive. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:40 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 3,278 | $3.24 | $10,620.72 |
DisclosureSEC source: 0001213900-21-006834 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 22:22 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 10,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-005448 · ownership.xml · derivative · entry 5 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,422 Underlying: Common Stock · 10,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable. F5 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 22:22 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 100 | $33.43 | $3,343.00 |
DisclosureSEC source: 0001213900-21-005448 · ownership.xml · nonDerivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,493 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 22:22 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 5,549 | $32.86 | $182,340.14 |
DisclosureSEC source: 0001213900-21-005448 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,593 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $32.42 to $33.41 per share, inclusive. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 22:22 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 4,351 | $31.77 | $138,231.27 |
DisclosureSEC source: 0001213900-21-005448 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,142 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $31.41 to $32.40 per share, inclusive. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 22:22 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 10,000 | $3.24 | $32,400.00 |
DisclosureSEC source: 0001213900-21-005448 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 00:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 600 | $35.15 | $21,090.00 |
DisclosureSEC source: 0001213900-21-004480 · ownership.xml · nonDerivative · entry 5 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,493 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F6 · price: Sales prices range from $35.00 to $35.56 per share, inclusive. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 00:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,300 | $35.29 | $45,877.00 |
DisclosureSEC source: 0001213900-21-004480 · ownership.xml · nonDerivative · entry 4 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,093 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F5 · price: Sales prices range from $35.01 to $35.51 per share, inclusive. Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 00:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 4,070 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-004480 · ownership.xml · derivative · entry 6 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,422 Underlying: Common Stock · 4,070 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Not applicable. F7 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 00:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 434 | $36.15 | $15,689.10 |
DisclosureSEC source: 0001213900-21-004480 · ownership.xml · nonDerivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,393 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $36.04 to $36.37 per share, inclusive. Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 00:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,736 | $35.44 | $61,523.84 |
DisclosureSEC source: 0001213900-21-004480 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,827 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.04 to $35.98 per share, inclusive. Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 00:29 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 4,070 | $3.24 | $13,186.80 |
DisclosureSEC source: 0001213900-21-004480 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:05 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 250,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-21-001414 · ownership.xml · derivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-01-07 F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period. F2 · derivative.exercise_date: The options vest 25% one year from the date of grant, and thereafter in equal quarterly increments of 6.25% over the following three years. The options are subject to forfeiture upon failure by the Issuer to reach certain corporate objectives in 2021. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 21:05 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 250,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-21-001414 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-01-07 F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:15 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 50,008 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-20-022883 · ownership.xml · derivative · entry 3 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,492 Underlying: Common Stock · 50,008 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:15 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Tax withholdingCommon Stock | 4,151 | $39.03 | $162,013.53 |
DisclosureSEC source: 0001213900-20-022883 · ownership.xml · nonDerivative · entry 2 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,493 F1 · shares: Reflects 4,151 shares withheld at the market price of $39.03 per share to fund the cashless exercise of 50,008 options owned by Mr. Traversa, which cashless exercise was approved in advance by the Board of Directors. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:15 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 50,008 | $3.24 | $162,025.92 |
DisclosureSEC source: 0001213900-20-022883 · ownership.xml · nonDerivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:58 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 350,000 | $43.47 Strike: $43.47 | $15,214,500.00 |
DisclosureSEC source: 0001213900-19-026859 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 21:03 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 1,700,000 | $2.20 Strike: $2.20 | $3,740,000.00 |
DisclosureSEC source: 0001213900-19-014037 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700,000 Underlying: Common Stock · 1,700,000 shares Expires 2029-07-29 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. In addition, 850,000 options shall be cancelled if Relmada's common stock is not approved for listing on the Nasdaq Stock Market LLC by December 31, 2019. Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 21:56 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 900,000 | $1.15 Strike: $1.15 | $1,035,000.00 |
DisclosureSEC source: 0001213900-18-017636 · ownership.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2028-12-20 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| October 19, 2017 Filed Oct 23, 2017 20:42 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 850,000 | $0.81 Strike: $0.81 | $688,500.00 |
DisclosureSEC source: 0001213900-17-010837 · f4101917traversa_relmada.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common stock · 850,000 shares Expires 2027-10-20 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:35 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 75,000 | $1.39 Strike: $1.39 | $104,250.00 |
DisclosureSEC source: 0001213900-17-002467 · f4031417traversa_actinium.xml · derivative · entry 1 TRAVERSA SERGIO · CIK 0001565832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.